Sequence: PCM: CWLSEAGPVVTVRALRGTGSW; Tat: YGRKKRRQRRR
| Experiment Id | EXP002019 |
|---|---|
| Paper | Cell Targeting Peptide Conjugation to siRNA Polyplexes for Effective Gene Silencing in Cardiomyocyte |
| Peptide | PCM + Tat |
| Delivery Success Class | no |
| In Vivo Flag | no |
| Uptake Confirmed | yes |
| Label Confidence | high |
| In Vitro Functional Effect | yes |
| Endosomal Escape Evidence | |
| Peptide Concentration | siRNA dose 50 nM (0.35 µg/well) |
| Rna Concentration | 50 nM |
| Mixing Ratio | PCM-siRNA : Tat-siRNA = 1:1 |
| Formulation Format | siRNA-pDNA/CD polyplex |
| Formulation Components | PCM-siRNA + Tat-siRNA + plasmid DNA + bioreducible polymer (poly(CBA-DAH)) |
| Size Nm | 145.00 |
| Zeta Mv | 10.00 |
| Model Scope | in_vitro |
| Model Type | in vitro |
| Cell Lines Or Primary Cells | H9C2 cardiomyocytes; NIH 3T3; Huh7; A549 |
| Animal Model | |
| Administration Route | |
| Output Type | gene knockdown / reporter expression |
| Output Value | Significant VEGF knockdown; increased GFP expression in cardiomyocytes |
| Output Units | |
| Output Notes | Functional gene silencing and reporter expression shown; enhanced vs non-targeted systems |
| Toxicity Notes | Cell viability >80%; no significant IFN-α induction |
| Curation Notes |